Silo Pharma Partners with Veloxity Labs for PTSD Therapy Study

Author: Owen Jenkins Updated: 05-14-2025 04:18 PM

Silo Pharma Engages Veloxity Labs for Vital Research

Silo Pharma, Inc. (Nasdaq: SILO), a pioneering company in the biopharmaceutical sector, has teamed up with Veloxity Labs, LLC to conduct a critical bioanalytical study. This partnership aims to support their investigational new drug (IND)-enabling study for SPC-15, designed as an innovative intranasal treatment for post-traumatic stress disorder (PTSD).

Importance of the Collaboration

In a recent announcement, Eric Weisblum, the CEO of Silo, expressed enthusiasm about the collaboration with Veloxity Labs. He stated, "We look forward to working with Veloxity Labs for GLP sample analysis in our current safety study of SPC-15." Weisblum emphasized the value of quick turnaround times and high-quality data, projecting that Veloxity will significantly contribute to the preclinical data necessary for advancing towards an IND approval for SPC-15.

Expected Timeline for FDA IND Process

Silo Pharma has plans to initiate the FDA IND process for SPC-15 in the near future. Once the IND is approved, the company anticipates proceeding to a first-in-human Phase 1 clinical trial, marking a pivotal step in bringing this therapy to those who need it most.

Overview of Silo Pharma's Mission

Silo Pharma is focused on developing treatments for various understudied conditions, which include stress-related psychiatric disorders, chronic pain, and diseases affecting the central nervous system (CNS). The company's innovative portfolio includes not only SPC-15 but also SP-26, targeting fibromyalgia and chronic pain, alongside other preclinical projects aimed at conditions like Alzheimer’s disease and multiple sclerosis.

Collaborative Research Efforts

The research initiatives at Silo Pharma are enhanced through partnerships with prestigious universities and laboratory facilities, fostering an environment of innovation. This collaboration ensures that the company remains at the forefront of the biopharmaceutical landscape.

Contact Information for Inquiries

For additional information about Silo Pharma's initiatives or opportunities for collaboration, interested parties can reach out via telephone at 800-705-0120 or email at investors@silopharma.com.

Frequently Asked Questions

What is SPC-15?

SPC-15 is an innovative intranasal therapy being developed to treat post-traumatic stress disorder (PTSD).

Who is collaborating with Silo Pharma on this project?

Silo Pharma has partnered with Veloxity Labs to conduct essential bioanalytical studies for SPC-15.

What is the significance of the FDA IND process?

The FDA IND process is crucial as it allows Silo Pharma to initiate clinical trials needed to assess the safety and efficacy of SPC-15 in humans.

How does Silo Pharma support innovative research?

Silo Pharma collaborates with leading universities and research laboratories, ensuring high standards and innovative approaches in its drug development.

How can investors stay informed about Silo Pharma's progress?

Investors can reach out to Silo Pharma's contact number or email for updates and information regarding their ongoing projects and developments.

About The Author

Hi there I'm 38-year-old author and financial consultant Owen Jenkins. Having worked in the financial sector for more than ten years, I am well-versed in the subtleties and complexity that mold our financial environment. Following a degree in finance, I worked in a number of financial institutions honing my abilities in market analysis, financial planning, and investment strategies.

My love is teaching others about investing and personal finance. My goal in writing many books and articles has been to demystify financial ideas and give readers the information they need to make wise financial decisions. I write with a direct, useful style that emphasizes doable suggestions for daily living.

Along with writing, I lead webinars and seminars where I impart knowledge on how to successfully negotiate the financial world. I also write for financial journals and show up as a guest expert on financial news programs a lot. Whether they are new to investing or want to improve their approach, my mission is to enable people to take charge of their financial futures.

Beyond work, I like to hike, play the guitar, and spend time with my family. I think that balance is crucial and want to encourage people to strike a balance between their financial aspirations and their hobbies. I want to help people succeed and achieve financial security through my work, so having a good influence.

Contact Owen Jenkins privately here. Or send an email with ATTN: Owen Jenkins as the subject to contact@investorshangout.com.

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.